---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-23-000121"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:16:11.934900+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q2 revenue $137.2M (+26% YoY); raises FY2023 revenue guidance to $545-550M

## Summary
- Revenue $137.2M (+26% YoY); clinical test volume 43,500 (+49%), biopharma tests 6,700 (+12%).
- Net loss $72.8M vs $229.4M prior year (includes fair value changes); Non-GAAP net loss $88.7M.
- Raised FY2023 revenue guidance to $545-550M (from $535-545M); expects operating expenses below 2022 levels.
- Cash $1.2B; completed public offering raising $381M net; Guardant360 now covered by all major U.S. commercial insurers.

## SEC filing metadata
- accession: 0001576280-23-000121
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000121/0001576280-23-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000121/gh-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-23-000121
- JSON: https://secwatch.observer/filing/0001576280-23-000121.json
- Plain text: https://secwatch.observer/filing/0001576280-23-000121.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the quarter ended June 30, 2023 results: revenue $137.2 million, net income $(0.67), EPS $(0.67). Guidance raised.
  - Period: the quarter ended June 30, 2023
  - Revenue: $137.2 million
  - Net income: $(0.67)
  - EPS: $(0.67)
  - Guidance: raised
  - Result: reported results
  source text: Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million PALO ALTO, Calif. August 3, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights • Revenue of $137.2 million for the second quarter of 2023, an increase of 26% over the second quarter of 2022 • Reported 43,500 tests to clinical customers and 6,700 tests to biopharmaceutical customers in the second quarter of 2023, representing increases of 49% and 12%, respectively, over the second quarter of 2022 Recent Operating Highlights • Received new commercial plan coverage from Anthem Blue Cross and Blue Shield, Aetna,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000121/0001576280-23-000121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.